What does PHARMADEFI do?

PHARMADEFI is a pharmacy in Arlon. Public Limited, started on 29 May 1989, 1 establishment.

What is the address of PHARMADEFI?

The registered office of PHARMADEFI is located at Route de Luxembourg 97, 6700 Arlon.

Is PHARMADEFI still active?

Yes. According to the CBE (29 October 2026) PHARMADEFI is active, legal situation “Normale toestand”, started on 29 May 1989.

Is PHARMADEFI registered on Peppol?

Yes, PHARMADEFI is registered on the Peppol network with ID 0208:0437576896.

What is the enterprise number of PHARMADEFI?

The enterprise number of PHARMADEFI is BE0437576896.

When was PHARMADEFI founded?

PHARMADEFI was founded on 29 May 1989.

Who are the directors of PHARMADEFI?

According to the 2025 annual accounts, the directors of PHARMADEFI are: Joëlle Denis, Olivier Groffy.

Is PHARMADEFI a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 29 May 1989; 5 annual accounts filed, latest fiscal year 2025; 2 directors known from the annual account.

How much profit did PHARMADEFI make in 2025?

PHARMADEFI posted a profit after taxes of € 158,135 in financial year 2025.

What is the revenue of PHARMADEFI?

As a small company, PHARMADEFI is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 691,409.

How much does an employee at PHARMADEFI earn?

The average wage cost per full-time employee at PHARMADEFI was € 79,600 in 2025: staff costs of € 254,567 for 3.2 FTE, according to the annual account at the National Bank. That is the employer's cost, not net pay.

How many employees does PHARMADEFI have?

According to the 2025 annual accounts, PHARMADEFI has 3.2 full-time equivalents (FTE).

PHARMADEFI (Public Limited) - Arlon - BE0437576896

Dossier PHARMADEFI, printed on 29 October 2026 from databakkes.be/en/0437576896/pharmadefi. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Warning lights

Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.

Shrinking team NBB

FTE fell two years in a row, from 4.2 to 3.2.

Financials

Financial year 2025

PHARMADEFI from Arlon, company number BE0437576896, closed financial year 2025 with a result of € 158,135 after tax. For that financial year PHARMADEFI recorded a gross margin of € 691,409 and equity of € 671,836. Compared with financial year 2024, the result moved from € 219,893 to € 158,135. The company is profitable. The buffer is growing. Debts are under control. The most recent annual accounts were filed with the National Bank of Belgium on August 20, 2026.

What it is worth Growing

€ 671,836

▲ 31% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Healthy

€ 158,135

▼ 28% vs 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 28,628

▲ 69% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Growing

Stays in the company

No dividend for 2025. Retained profit grew to € 606,836.

People and assets in 2025

Full-time equivalents

3.2

▼ 0.1 vs 2024

Average over the fiscal year, from the social balance sheet.

Wage cost

€ 254,567

▲ 6% vs 2024

€ 79,600 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.

Vehicles and equipment

€ 105

▼ 97% vs 2024

Book value of vehicles, furniture and equipment.

Debts at end 2025

Bank debt ≈ 6 years to go The accounts give the long-term loan and the part due within the year. The remainder divided by that part is the number of years at an equal pace; a new loan or early repayment changes it.

€ 1 million

▲ 1% vs 2024

€ 137,081 is repaid this year. At this pace the long-term loan is gone in ≈ 6 years.

Owed to suppliers

€ 340,754

▼ 6% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes and wages

€ 60,138

▼ 15% vs 2024

Taxes, VAT and social contributions still to pay.

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 757,437 Gross margin 2022: € 757,437 First fiscal year in the series	€ 720,371 Gross margin 2023: € 720,371 ▼ 5% vs 2022 (€ 757,437) Unfavourable step	€ 754,719 Gross margin 2024: € 754,719 ▲ 5% vs 2023 (€ 720,371) Favourable step	€ 691,409 Gross margin 2025: € 691,409 ▼ 8% vs 2024 (€ 754,719) Unfavourable step	▼ 8%
Profit after taxes	€ 235,695 Profit after taxes 2022: € 235,695 First fiscal year in the series	€ 148,771 Profit after taxes 2023: € 148,771 ▼ 37% vs 2022 (€ 235,695) Unfavourable step	€ 219,893 Profit after taxes 2024: € 219,893 ▲ 48% vs 2023 (€ 148,771) Favourable step	€ 158,135 Profit after taxes 2025: € 158,135 ▼ 28% vs 2024 (€ 219,893) Unfavourable step	▼ 28%
Equity	€ 145,037 Equity 2022: € 145,037 First fiscal year in the series	€ 293,808 Equity 2023: € 293,808 ▲ 103% vs 2022 (€ 145,037) Favourable step	€ 513,701 Equity 2024: € 513,701 ▲ 75% vs 2023 (€ 293,808) Favourable step	€ 671,836 Equity 2025: € 671,836 ▲ 31% vs 2024 (€ 513,701) Favourable step	▲ 31%
Total debts	€ 2,335,742 Total debts 2022: € 2,335,742 First fiscal year in the series	€ 2,167,741 Total debts 2023: € 2,167,741 ▼ 7% vs 2022 (€ 2,335,742) Favourable step	€ 1,926,668 Total debts 2024: € 1,926,668 ▼ 11% vs 2023 (€ 2,167,741) Favourable step	€ 1,804,392 Total debts 2025: € 1,804,392 ▼ 6% vs 2024 (€ 1,926,668) Favourable step	▼ 6%
Cash	€ 21,216 Cash 2022: € 21,216 First fiscal year in the series	€ 28,980 Cash 2023: € 28,980 ▲ 37% vs 2022 (€ 21,216) Favourable step	€ 16,929 Cash 2024: € 16,929 ▼ 42% vs 2023 (€ 28,980) Unfavourable step	€ 28,628 Cash 2025: € 28,628 ▲ 69% vs 2024 (€ 16,929) Favourable step	▲ 69%
Land & buildings	€ 1,345,513 Land & buildings 2022: € 1,345,513 First fiscal year in the series	€ 1,199,574 Land & buildings 2023: € 1,199,574 ▼ 11% vs 2022 (€ 1,345,513) Unchanged	€ 1,053,876 Land & buildings 2024: € 1,053,876 ▼ 12% vs 2023 (€ 1,199,574) Unchanged	€ 903,006 Land & buildings 2025: € 903,006 ▼ 14% vs 2024 (€ 1,053,876) Unchanged	▼ 14%
Retained profit	€ 80,037 Retained profit 2022: € 80,037 First fiscal year in the series	€ 228,808 Retained profit 2023: € 228,808 ▲ 186% vs 2022 (€ 80,037) Favourable step	€ 448,701 Retained profit 2024: € 448,701 ▲ 96% vs 2023 (€ 228,808) Favourable step	€ 606,836 Retained profit 2025: € 606,836 ▲ 35% vs 2024 (€ 448,701) Favourable step	▲ 35%
Dividend	€ 100,000 Dividend 2022: € 100,000 First fiscal year in the series	€ 0 Dividend 2023: € 0 ▼ 100% vs 2022 (€ 100,000) Unchanged	€ 0 Dividend 2024: € 0 Unchanged (€ 0) Unchanged	€ 0 Dividend 2025: € 0 Unchanged (€ 0) Unchanged
Bank debt	€ 1,245,441 Bank debt 2022: € 1,245,441 First fiscal year in the series	€ 1,114,236 Bank debt 2023: € 1,114,236 ▼ 11% vs 2022 (€ 1,245,441) Favourable step	€ 995,654 Bank debt 2024: € 995,654 ▼ 11% vs 2023 (€ 1,114,236) Favourable step	€ 1,006,605 Bank debt 2025: € 1,006,605 ▲ 1% vs 2024 (€ 995,654) Unfavourable step	▲ 1%
Balance sheet total	€ 2,494,670 Balance sheet total 2022: € 2,494,670 First fiscal year in the series	€ 2,472,288 Balance sheet total 2023: € 2,472,288 ▼ 1% vs 2022 (€ 2,494,670) Unchanged	€ 2,447,957 Balance sheet total 2024: € 2,447,957 ▼ 1% vs 2023 (€ 2,472,288) Unchanged	€ 2,480,665 Balance sheet total 2025: € 2,480,665 ▲ 1% vs 2024 (€ 2,447,957) Unchanged	▲ 1%
Employees (FTE)	4.7 Employees (FTE) 2022: 4.7 First fiscal year in the series	4.2 Employees (FTE) 2023: 4.2 ▼ 0.5 vs 2022 (4.7) Unchanged	3.3 Employees (FTE) 2024: 3.3 ▼ 0.9 vs 2023 (4.2) Unchanged	3.2 Employees (FTE) 2025: 3.2 ▼ 0.1 vs 2024 (3.3) Unchanged	▼ 0.1

Key figures of PHARMADEFI, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to PHARMADEFI?

What happened at PHARMADEFI in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Aug 20, 2026 New annual accounts for financial year 2025: profit of € 158,135 (▼ 28% vs 2024). filed late Source: NBB ↗
Jun 16, 1989 New establishment in Arlon. KBO
May 29, 1989 Start of the company according to the CBE. KBO

In short

From € 235,695 profit in 2022 to € 158,135 profit in 2025.

Paid € 210,632 in corporate taxes since 2022.

Best year ever: 2022, with € 235,695 profit.

On average € 216,100 of value added per employee in 2025.

Original PDFs at the National Bank ↗

Management

ExpansionPharma 99.9%

The stake of ExpansionPharma comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.

PHARMADEFI

Behind PHARMADEFI are Joëlle Denis and Olivier Groffy. The shares are held by ExpansionPharma (99.9%).

Directors

According to the 2025 annual accounts

Joëlle Denis

Managing director

Also active at: AKT - CCI Luxembourg Belge, Pharmacie Forthomme, Pharmacie BODARD, PHARMACIE HITTELET, L.O.J'M, PHARMALORRAINE, ExpansionPharma, DYNAMIC PHARMA +1 more

Olivier Groffy

Managing director

Also active at: Pharmacie Forthomme, Pharmacie BODARD, PHARMACIE HITTELET, L.O.J'M, PHARMALORRAINE, ExpansionPharma, DYNAMIC PHARMA, delta SUD PHARMA

Shareholders

ExpansionPharma

99.9%

Participations

No participations in other companies reported.

Establishments

Establishment units

Physical locations of this company

Registered office

Route de Luxembourg 97

6700 Arlon

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number

0437.576.896

VAT number

BE 0437.576.896

Registered office

Route de Luxembourg 97, 6700 Arlon

Names & denominations

PHARMADEFI

Enterprise type

Rechtspersoon

Legal form

Public limited company

Legal situation

Normale toestand

Start date

29 May 1989

Peppol

Active · Active since 26 Jan 2026

Contact

[email protected] +3263224426

Activities · NACE

Detailhandel in farmaceutische producten

Apothekers

View on CBE Public ↗ Annual accounts (NBB) ↗

PHARMADEFI

Warning lights

Financials

What happened to PHARMADEFI?

Management

Directors

Shareholders

Participations

Establishments

Establishment units

Details

Frequently asked questions